Monopar Therapeutics (MNPR) Total Liabilities (2016 - 2025)

Monopar Therapeutics has disclosed Total Liabilities across 10 years of filings, most recently posting $2.9 million for Q4 2025.

• Total Liabilities for Q4 2025 came in at $2.9 million, down 44.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.9 million (down 44.99% YoY), and the FY2025 annual result was $2.9 million, down 44.99% from the prior year.
• Total Liabilities came in at $2.9 million for Q4 2025 at Monopar Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $5.3 million in Q4 2024 to a low of $806272.0 in Q1 2021.
• The 5-year median for Total Liabilities is $1.7 million (2023), against an average of $2.0 million.
• Peak annual rise in Total Liabilities reached 198.98% in 2024, while the deepest fall reached 56.45% in 2024.
• Monopar Therapeutics' Total Liabilities stood at $1.6 million in 2021, then jumped by 98.5% to $3.1 million in 2022, then tumbled by 43.98% to $1.8 million in 2023, then jumped by 198.98% to $5.3 million in 2024, then plunged by 44.99% to $2.9 million in 2025.
• The last three Total Liabilities figures came in at $2.9 million (Q4 2025), $2.6 million (Q3 2025), and $1.7 million (Q2 2025), per Business Quant data.